NCT06700369View on ClinicalTrials.gov

De-escalation of Neoadjuvant Chemotherapy Regimens With Targeted Therapy Among HER2 Positive Patients

RecruitingOBSERVATIONAL

Enrollment

519

Participants

Timeline

Start Date

January 1, 2015

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2031

Conditions

HER2-positive Breast Cancer

Trial Locations (1)

100044

RECRUITING

Peking University People's Hospital, Beijing

All Listed Sponsors

lead

Shu Wang

OTHER